Virtual Reality Therapy for Gastrointestinal Cancer Pain
Trial Summary
What is the purpose of this trial?
Patients with digestive tract malignancy often experience severe and unremitting abdominal pain that negatively affects physical, emotional, and social function, as well as health related quality of life (HRQOL). Therapeutic virtual reality (VR) has emerged as a promising and evidence-based treatment modality for cancer pain. Users of VR wear a pair of goggles with a close-proximity screen in front of the eyes that creates a sensation of being transported into lifelike, three-dimensional worlds. To date, VR has been limited to short-term clinical trials for cancer pain. Moreover, limited research exists on theory-based VR modalities beyond mere distraction, such as VR that employs acceptance and commitment therapy (ACT) with components of biofeedback and mindfulness. To bridge these gaps, this study seeks to: (1) assess the impact of immersive VR on patient-reported outcomes (PROs), including pain, activity metrics, and opioid use among patients with visceral pain from a digestive tract malignancy; (2) assess differences in PROs, activity metrics, and opioid use between skills-based VR therapy vs. distraction VR therapy; and (3) determine patient-level predictors of VR treatment response in visceral cancer pain. To address these aims, the study will measure PROs and opioid use in 360 patients randomized among 3 groups and follow them for 60 days after enrollment: (1) an enhanced VR group receiving skills-based VR; (2) a distraction-based VR group receiving patient-selected VR videos; and (3) a VR sham control group using a VR headset with 2-D content. The results will inform best practices for the implementation of VR for visceral cancer pain management and guide selection of patient-tailored experiences.
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications. However, it does mention that the study will measure opioid use, so you might be able to continue your current pain management medications.
What data supports the effectiveness of the treatment Virtual Reality Therapy for managing pain in gastrointestinal cancer patients?
Research shows that virtual reality (VR) can help reduce pain and anxiety in cancer patients, including those undergoing medical procedures and chemotherapy. Studies have found that VR-based interventions significantly improve symptoms like pain, anxiety, and depression, suggesting it could be a helpful tool for managing cancer-related symptoms.12345
Is Virtual Reality Therapy safe for humans?
How is virtual reality treatment different from other treatments for gastrointestinal cancer pain?
Virtual reality treatment is unique because it immerses patients in a multisensory experience to relieve pain, unlike traditional medications that may have side effects or only partially relieve symptoms. This non-drug approach allows patients to self-practice pain management techniques in a standardized way, offering a novel solution for chronic pain management.1112131415
Research Team
Brennan Spiegel, MD, MSHS
Principal Investigator
Cedars-Sinai Medical Center
Scott Irwin, MD, PhD
Principal Investigator
Cedars-Sinai Medical Center
Eligibility Criteria
This trial is for adults with certain types of digestive tract cancers (like colon, liver, or stomach cancer) who are not planning surgery soon and have significant pain. They must be able to read/write in English and score high on a specific pain scale. People can't join if they have seizures, severe visual impairments, cognitive issues that affect understanding the study, brain metastases, or a life expectancy less than 3 months.Inclusion Criteria
Exclusion Criteria
Trial Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants are randomized into three groups to receive either skills-based VR therapy, distraction VR therapy, or sham VR for pain management. They will use the VR headset daily for four weeks.
Follow-up
Participants are monitored for safety and effectiveness after treatment, with assessments of patient-reported outcomes, opioid use, and other metrics.
Long-term monitoring
Participants continue to be monitored for changes in pain management and quality of life metrics.
Treatment Details
Interventions
- Virtual Reality (Behavioural Intervention)
Find a Clinic Near You
Who Is Running the Clinical Trial?
Cedars-Sinai Medical Center
Lead Sponsor
David E. Cohen
Cedars-Sinai Medical Center
Chief Medical Officer
MD and PhD in Physiology and Biophysics from Harvard University
Peter L. Slavin
Cedars-Sinai Medical Center
Chief Executive Officer
MD from Harvard Medical School, MBA from Harvard Business School
National Cancer Institute (NCI)
Collaborator
Dr. Douglas R. Lowy
National Cancer Institute (NCI)
Chief Executive Officer since 2023
MD from New York University School of Medicine
Dr. Monica Bertagnolli
National Cancer Institute (NCI)
Chief Medical Officer since 2022
MD from Harvard Medical School